<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MBBS Pathology Notes: Skin</title>
    <link href="https://fonts.googleapis.com/css2?family=Kalam:wght@300;400;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --neon-yellow: #f4ff40; /* Neon yellowish highlighter */
            --marker-green: #daffb3; /* Natural light green marker */
            --ink-color: #2c2c2c; /* Dark grey/black ink look */
            --paper-white: #ffffff; /* Pure white page */
            --box-bg: #fffef0; /* Subtle warm tint for boxes */
            --border-color: #333;
        }

        * {
            box-sizing: border-box;
        }

        body {
            background-color: #525659; /* Grey background behind the paper */
            font-family: 'Kalam', cursive;
            color: var(--ink-color);
            margin: 0;
            padding: 20px;
            display: flex;
            justify-content: center;
            line-height: 1.6;
            font-size: 18px; /* Readable handwritten size */
        }

        /* A4 Paper Simulation */
        .page-container {
            background-color: var(--paper-white);
            width: 210mm; /* A4 width */
            min-height: 297mm; /* A4 height minimum */
            padding: 25mm; /* Standard margins */
            box-shadow: 0 4px 15px rgba(0,0,0,0.3);
            position: relative;
            margin-bottom: 20px;
        }

        /* Typography */
        h1 {
            font-size: 32px;
            text-align: center;
            text-decoration: underline;
            text-decoration-color: var(--neon-yellow);
            text-decoration-thickness: 5px;
            margin-bottom: 40px;
            color: #000;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        h2 {
            font-size: 26px;
            border-bottom: 3px solid var(--marker-green);
            padding-bottom: 5px;
            margin-top: 40px;
            color: #1a1a1a;
            display: inline-block;
            width: 100%;
        }

        h3 {
            font-size: 22px;
            font-weight: 700;
            margin-top: 25px;
            color: #333;
            text-decoration: underline;
        }

        h4 {
            font-size: 20px;
            font-weight: 700;
            margin-top: 15px;
            color: #444;
        }

        p {
            margin-bottom: 15px;
            text-align: justify;
        }

        ul, ol {
            margin-bottom: 15px;
            padding-left: 25px;
        }

        li {
            margin-bottom: 8px;
        }

        /* Highlighting Classes */
        .highlight-neon {
            background-color: var(--neon-yellow);
            padding: 2px 5px;
            border-radius: 4px;
            font-weight: bold;
        }

        .highlight-green {
            background-color: var(--marker-green);
            padding: 2px 5px;
            border-radius: 4px;
            font-weight: bold;
        }

        strong {
            font-weight: 700;
        }

        /* Hand-drawn Box Style */
        .hand-drawn-box {
            border: 2px solid var(--border-color);
            /* Irregular border radius for hand-drawn effect */
            border-radius: 2px 20px 3px 25px / 25px 3px 20px 2px;
            padding: 20px;
            margin: 25px 0;
            background-color: var(--box-bg); 
            box-shadow: 3px 4px 0px rgba(0,0,0,0.1);
        }

        /* Table Styling */
        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: 20px 0;
            font-size: 16px;
            border: 2px solid var(--border-color);
            border-radius: 8px;
            overflow: hidden;
        }

        th, td {
            border-right: 1px solid var(--border-color);
            border-bottom: 1px solid var(--border-color);
            padding: 12px;
            text-align: left;
            vertical-align: top;
        }

        th {
            background-color: var(--marker-green);
            font-weight: bold;
            border-bottom: 2px solid var(--border-color);
        }

        tr:last-child td {
            border-bottom: none;
        }
        
        tr td:last-child, tr th:last-child {
            border-right: none;
        }

        /* Model Answer Section */
        .qa-section {
            border-left: 4px solid var(--neon-yellow);
            padding-left: 20px;
            margin-top: 30px;
        }

        /* Print Settings */
        @media print {
            body {
                background-color: white;
                padding: 0;
            }
            .page-container {
                width: 100%;
                box-shadow: none;
                margin: 0;
                padding: 15mm;
            }
            /* Ensure background colors print */
            * {
                -webkit-print-color-adjust: exact !important;
                print-color-adjust: exact !important;
            }
            h1, h2, h3 {
                page-break-after: avoid;
            }
            table, .hand-drawn-box, li {
                page-break-inside: avoid;
            }
        }

        /* Responsive Mobile */
        @media (max-width: 800px) {
            .page-container {
                width: 100%;
                padding: 15px;
            }
            table {
                font-size: 14px;
                display: block;
                overflow-x: auto;
            }
        }
    </style>
</head>
<body>

<div class="page-container">

    <h1>TOPIC 11: SKIN PATHOLOGY</h1>

    <p><strong>Syllabus Scope:</strong> Squamous Cell Carcinoma, Basal Cell Carcinoma, and Malignant Melanoma (Pathogenesis, Morphology, and Natural History).</p>

    <h2>1. SQUAMOUS CELL CARCINOMA (SCC) OF SKIN</h2>

    <p><strong>Definition:</strong> A malignant tumor arising from the keratinizing stratified squamous epithelium of the epidermis.</p>

    <h3>Risk Factors</h3>
    <ul>
        <li><strong>Sun Exposure:</strong> Chronic exposure to UV radiation (UVB is most carcinogenic) is the #1 cause.</li>
        <li><strong>Chemical Carcinogens:</strong> Arsenic (in drinking water/pesticides), Tars, Oils, Soot.</li>
        <li><strong>Ionizing Radiation:</strong> X-rays, Gamma rays.</li>
        <li><strong>Precursor Lesions:</strong> <span class="highlight-neon">Actinic Keratosis</span> (Solar keratosis), Bowen's Disease (SCC in situ).</li>
        <li><strong>Chronic Inflammation:</strong> Chronic ulcers (Marjolin's ulcer in burn scars), Sinus tracts (Osteomyelitis).</li>
        <li><strong>Immunosuppression:</strong> Organ transplant recipients, Xeroderma Pigmentosum (DNA repair defect).</li>
    </ul>

    <h3>Pathogenesis</h3>
    <ul>
        <li><strong>UV Radiation:</strong> Causes DNA damage (formation of pyrimidine dimers). If repair fails (e.g., XP), mutations accumulate.</li>
        <li><strong>Genetic Mutations:</strong>
            <ul>
                <li><span class="highlight-green">TP53 mutations:</span> An early event (often seen in actinic keratosis).</li>
                <li><strong>HRAS</strong> activating mutations.</li>
                <li>Loss of Notch receptor signaling (which normally promotes differentiation).</li>
            </ul>
        </li>
    </ul>

    <h3>Pathology (Morphology)</h3>
    <div class="hand-drawn-box">
        <p><strong>Gross Features:</strong></p>
        <ul>
            <li>Usually on sun-exposed sites (Face, Ears, Hands).</li>
            <li>Starts as a scaling, indurated (hard) plaque or nodule.</li>
            <li>Progresses to an <strong>Ulcerative</strong> lesion with raised, everted edges or a <strong>Fungating</strong> mass.</li>
        </ul>
        <p><strong>Microscopic Features:</strong></p>
        <ul>
            <li>Invasive nests and cords of malignant squamous epithelial cells extending into the dermis.</li>
            <li><strong>Keratin Pearls:</strong> Concentric layers of keratinization (Hallmark of well-differentiated SCC).</li>
            <li><strong>Intercellular Bridges:</strong> Prickles visible between cells.</li>
            <li>Atypia: Pleomorphism, hyperchromasia, abnormal mitoses.</li>
        </ul>
    </div>

    <h3>Natural History</h3>
    <ul>
        <li>Generally slow-growing.</li>
        <li><strong>Metastasis:</strong> Less common than in mucosal SCC (e.g., oral cancer). Occurs late to regional lymph nodes (< 5% risk in sun-induced SCC).</li>
        <li><em>Note:</em> SCC arising in burn scars/ulcers is more aggressive.</li>
    </ul>

    <hr>

    <h2>2. BASAL CELL CARCINOMA (BCC)</h2>

    <p><strong>Definition:</strong> The most common invasive cancer in humans. It is a locally aggressive but rarely metastasizing tumor arising from the basal layer of the epidermis or hair follicles.</p>

    <h3>Risk Factors</h3>
    <ul>
        <li><strong>Sun Exposure:</strong> Chronic UV exposure (cumulative).</li>
        <li><strong>Skin Type:</strong> Fair-skinned individuals (Types I and II) who burn easily.</li>
        <li><strong>Immune suppression.</strong></li>
        <li><strong>Genetic Syndromes:</strong> <span class="highlight-green">Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)</span>.</li>
    </ul>

    <h3>Pathogenesis</h3>
    <p>Almost all BCCs have dysregulation of the <strong>Hedgehog Signaling Pathway</strong>.</p>
    <ul>
        <li><strong>PTCH Gene:</strong> A tumor suppressor gene on Chromosome 9q22.</li>
        <li>Normal PTCH inhibits the SMO (Smoothened) protein.</li>
        <li><strong>Mutation:</strong> Loss of PTCH function (or activating mutation of SMO) leads to constitutive activation of the Hedgehog pathway, driving cell proliferation.</li>
    </ul>

    <h3>Pathology (Morphology)</h3>
    <div class="hand-drawn-box">
        <p><strong>Gross Features:</strong></p>
        <ul>
            <li>Commonly on face (above line joining angle of mouth and ear lobule).</li>
            <li><strong>Nodulo-ulcerative type:</strong> Pearly, translucent papule/nodule with <span class="highlight-neon">Telangiectasia</span> (dilated vessels) on surface.</li>
            <li><strong>Rodent Ulcer:</strong> Central ulceration with rolled, beaded, pearly margins. It "gnaws" into underlying tissue.</li>
        </ul>
        <p><strong>Microscopic Features:</strong></p>
        <ul>
            <li>Nests of uniform basaloid cells (resembling stratum basale) invading the dermis.</li>
            <li><span class="highlight-green">Peripheral Palisading:</span> The cells at the periphery of the nests are arranged parallel to each other (like a picket fence).</li>
            <li><strong>Retraction Clefting:</strong> Separation artifact between the tumor nest and stroma.</li>
            <li>Stroma is mucinous.</li>
        </ul>
    </div>

    <h3>Natural History</h3>
    <ul>
        <li>Slow growing.</li>
        <li><strong>Locally Invasive:</strong> Can destroy underlying cartilage, bone, and soft tissue ("Rodent ulcer").</li>
        <li><strong>Metastasis:</strong> Extremely rare.</li>
    </ul>

    <hr>

    <h2>3. DISTINGUISHING FEATURES: NEVUS VS. MELANOMA</h2>
    <p>Use the <strong>ABCDE Rule</strong> for clinical differentiation.</p>

    <table>
        <thead>
            <tr>
                <th>Feature</th>
                <th>Benign Nevus (Mole)</th>
                <th>Malignant Melanoma</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td><strong>A - Asymmetry</strong></td>
                <td>Symmetrical.</td>
                <td><span class="highlight-neon">Asymmetrical</span>.</td>
            </tr>
            <tr>
                <td><strong>B - Borders</strong></td>
                <td>Regular, smooth, defined.</td>
                <td>Irregular, notched, scalloped.</td>
            </tr>
            <tr>
                <td><strong>C - Color</strong></td>
                <td>Uniform (tan or brown).</td>
                <td><span class="highlight-green">Variegated</span> (black, brown, red, blue, white).</td>
            </tr>
            <tr>
                <td><strong>D - Diameter</strong></td>
                <td>Usually < 6 mm.</td>
                <td>Usually > 6 mm.</td>
            </tr>
            <tr>
                <td><strong>E - Evolution</strong></td>
                <td>Stable over time.</td>
                <td>Rapid change in size, shape, color, or symptoms (itching/bleeding).</td>
            </tr>
            <tr>
                <td><strong>Microscopy</strong></td>
                <td>Maturation (cells get smaller/deeper). No atypia.</td>
                <td>No maturation (deep cells large). Cytologic atypia, Mitoses, upward spread (<span class="highlight-neon">Pagetoid spread</span>).</td>
            </tr>
        </tbody>
    </table>

    <hr>

    <h2>4. MALIGNANT MELANOMA</h2>

    <p><strong>Definition:</strong> A malignant tumor arising from melanocytes. It is the most deadly form of skin cancer due to its high metastatic potential.</p>

    <h3>Etiology and Risk Factors</h3>
    <ul>
        <li><strong>Sunlight:</strong> Intense intermittent exposure (Sunburns) is more damaging than chronic exposure. <span class="highlight-neon">UVB</span> is the main culprit.</li>
        <li><strong>Pre-existing Lesions:</strong> <span class="highlight-green">Dysplastic Nevi</span> (Multiple atypical moles).</li>
        <li><strong>Family History:</strong> Familial Melanoma.</li>
        <li><strong>Pigmentation:</strong> Light skin, blue eyes, blonde/red hair (Pheomelanin), inability to tan.</li>
        <li><strong>Xeroderma Pigmentosum.</strong></li>
    </ul>

    <h3>Pathogenesis (Genetics)</h3>
    <ol>
        <li><strong>BRAF Mutations (40-50%):</strong> Activating mutation in <strong>BRAF V600E</strong> kinase (part of RAS/RAF/MEK pathway) drives proliferation.</li>
        <li><strong>CDKN2A Mutation:</strong> Loss of tumor suppressors <strong>p16/INK4a</strong> (cell cycle control). Common in familial cases.</li>
        <li><strong>KIT Mutations:</strong> Seen in mucosal and acral melanomas.</li>
        <li><strong>TERT Promoter Mutations:</strong> Maintains telomerase (immortality).</li>
    </ol>

    <h3>Morphology (Growth Phases)</h3>
    <p>Melanoma progression typically shows two phases:</p>
    <div class="hand-drawn-box">
        <p><strong>1. Radial Growth Phase (Horizontal):</strong></p>
        <ul>
            <li>Initial phase. Tumor cells spread laterally within the epidermis and superficial dermis.</li>
            <li>Lacks capacity to metastasize.</li>
            <li><em>Types showing this:</em> Superficial Spreading Melanoma, Lentigo Maligna.</li>
        </ul>
        <p><strong>2. Vertical Growth Phase (Invasive):</strong></p>
        <ul>
            <li>Tumor cells invade downward into the deep dermis.</li>
            <li>Appearance of a nodule.</li>
            <li><strong>Metastatic potential emerges.</strong></li>
            <li><em>Types showing this:</em> Nodular Melanoma (starts directly in vertical phase).</li>
        </ul>
    </div>

    <p><strong>Microscopy:</strong> Large, pleomorphic cells with prominent eosinophilic nucleoli ("Cherry red nucleoli"). Pigment (melanin) may or may not be present (Amelanotic melanoma). HMB-45 and S-100 positive.</p>

    <h3>Clinical Features</h3>
    <ul>
        <li>Change in a mole (ABCDE rule).</li>
        <li>Itching or pain (early sign).</li>
        <li>Ulceration or bleeding (late sign).</li>
        <li><strong>Subtypes:</strong>
            <ul>
                <li><em>Superficial Spreading (70%):</em> Flat, irregular plaque. Sun-exposed skin.</li>
                <li><em>Nodular (15%):</em> Dome-shaped blue/black nodule. Rapid growth. Aggressive.</li>
                <li><em>Lentigo Maligna:</em> Face of elderly ("Hutchinson's freckle"). Slow growing.</li>
                <li><em>Acral Lentiginous:</em> Palms, soles, subungual. Most common type in dark-skinned individuals. Not UV-related.</li>
            </ul>
        </li>
    </ul>

    <h3>Metastases and Prognosis</h3>
    <ul>
        <li><strong>Prognostic Factor:</strong> The most important factor is the <strong>Depth of Invasion</strong> (<span class="highlight-neon">Breslow Thickness</span>).
            <ul>
                <li>< 1 mm: Good prognosis.</li>
                <li>> 4 mm: Poor prognosis.</li>
            </ul>
        </li>
        <li><strong>Spread:</strong>
            <ul>
                <li><em>Lymphatic:</em> Regional lymph nodes (Sentinel node biopsy is crucial).</li>
                <li><em>Hematogenous:</em> Liver, Lungs, Brain (Melanoma loves the brain), Heart.</li>
            </ul>
        </li>
    </ul>

    <hr>

    <h2 style="color: #d32f2f; border-color: #d32f2f;">IMPORTANT UNIVERSITY QUESTIONS</h2>

    <div class="qa-section">
        <h3>Q1: Classify Skin Cancers. Describe the Pathogenesis and Morphology of Basal Cell Carcinoma (BCC).</h3>
        <p><strong>Introduction:</strong> Skin cancers are broadly divided into Melanoma and Non-Melanoma Skin Cancers (NMSC). NMSCs include Basal Cell Carcinoma (most common) and Squamous Cell Carcinoma.</p>
        <p><strong>Body:</strong>
            <br><strong>Pathogenesis of BCC:</strong> It is driven by the dysregulation of the <strong>Hedgehog Pathway</strong>. Mutations in the <em>PTCH1</em> tumor suppressor gene (often UV-induced) prevent it from inhibiting SMO, leading to uncontrolled cell growth. This is also seen in Gorlin Syndrome.
            <br><strong>Morphology:</strong>
            <ul>
                <li><em>Gross:</em> A pearly, translucent nodule with telangiectasia. May ulcerate centrally ("Rodent Ulcer").</li>
                <li><em>Microscopy:</em> Nests of basaloid cells originating from the epidermis. The peripheral cells show <strong>Palisading</strong> (parallel alignment). Retraction artifacts (clefts) are seen between tumor nests and stroma.</li>
            </ul>
        </p>
        <p><strong>Conclusion:</strong> BCC is locally invasive ("Rodent ulcer") but virtually never metastasizes.</p>
    </div>

    <div class="qa-section">
        <h3>Q2: Differentiate between Benign Nevus and Melanoma. Discuss the Prognostic Factors of Melanoma.</h3>
        <p><strong>Introduction:</strong> Distinguishing a benign mole from melanoma is critical as melanoma is highly lethal.</p>
        <p><strong>Body:</strong>
            <br><strong>Differences:</strong> (Use ABCDE rule).
            <ul>
                <li>Nevus: Symmetrical, Regular borders, Uniform color, Diameter <6mm. Micro: Maturation present.</li>
                <li>Melanoma: Asymmetrical, Irregular borders, Variegated color, Diameter >6mm. Micro: No maturation, atypical mitoses, pagetoid spread.</li>
            </ul>
            <br><strong>Prognostic Factors:</strong>
            <ol>
                <li><strong>Breslow Thickness:</strong> Vertical depth of tumor (Most important). Thinner is better.</li>
                <li><strong>Ulceration:</strong> Presence indicates worse prognosis.</li>
                <li><strong>Mitotic Rate:</strong> High rate is worse.</li>
                <li><strong>Lymph Node Status:</strong> Sentinel node positivity decreases survival.</li>
            </ol>
        </p>
        <p><strong>Conclusion:</strong> Early detection while the tumor is in the radial growth phase is the key to survival.</p>
    </div>

</div>

</body>
</html>